A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge

NCT05884242 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Adalimumab
DRUG: Lipopolysaccharide (LPS)

Sponsor

Janssen Research & Development, LLC